CRISPR 精准切碎近半数癌症突变
推荐指数 51.0 NO. 018 · 2026.06.13
发布2026/06/12Score432Comments112
为什么值得看
加州大学团队开发染色质 shredding 技术，靶向 p53 突变（占癌症病例近50%）选择性摧毁癌细胞，包括传统认为"不可成药"的类型。若临床转化成功，将打开庞大却长期被忽视的药物靶点。
编辑判断
p53 被称为"基因组守护者"，制药界追逐三十年未能成药，核心难点是小分子难以恢复突变蛋白功能。这篇工作的聪明之处在于彻底换路——不修复、直接 shredding，把"不可成药"变成"不需要成药"。
关键悬念是递送系统：CRISPR 体内递送效率仍是瓶颈，实体瘤渗透更难。论文是否解决了肝外靶向递送？这是判断临床转化时间尺度的核心指标，建议直接翻 methods 里的 AAV 血清型或 LNP 配方数据。
做 AI+药物设计的团队也可关注：这类"合成致死"新机制是否值得用虚拟筛选或 AlphaFold 辅助优化 sgRNA 特异性。
社区反馈
意见分歧 100 条评论
核心争论：生物技术突破是临近爆发还是仍处早期，资源为何流向广告而非医疗
I hope this finally works out. I remember almost exactly ten years ago I got excited about one of these proposed cancer cures, tried to talk about it at lunch with my coworkers, and they laughed at me for believing.
I'm pretty optimistic. I think it's a threshold question where we need a number of basic technologies to all get over certain bars before the floodgates start to open. Over the past 1-2 decades there has been unbelievable progress at the basic technology level but most people are unimpressed because
So we're waiting for the Apple of the medical world to take a bunch of preexisting things to be applied together in a way that makes the whole much more valuable than the pieces. Or we need all of the individual lions to come together to make the Voltron?